Nifedipine: 30 years of clinical experience
Abstract
The article contains information on main pharmacological properties of nifedipine, its indications, specific features of various medicinal forms. The present experience of long-term nifedipine treatment is analyzed, according to its influence on clinical outcomes.
About the Author
S. Yu. Martsevich
State Research Center for Preventive Medicine, Ministry of Health of the Russian Federation, Moscow
Russian Federation
Russian Federation
References
1. Vater W, Kroneberg G, Hoffmeister F, et al. Zur Pharmacologie von 4-(2’Nitrophenyl)-2,6-dimethyl-1,4-dihidropyridin-3,5- dicarbonsauredim ethylester (Bay a 1040, Nifedipine). Arzneim. Forsch 1972; 22: 1-8.
2. Kleinbloesem CH, van Brummelen P, Faber H, Breimer DD. Pharmacokinetics and hemodynamic effects of long-term nifedipine treatment in hypertensive patients. J Cardiovasc Pharmacol 1987; 9: 202-8.
3. Krakoff LR, Bravo EL, Tuck ML, et al. Nifedipine gastrointestinal therapeutic system in the treatment of hypertension. Am J Hypertens 1990; 3: 318S-25.
4. Guidelines Committee. 2003 European Society of HypertensionEuropean Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
5. Stone P, Turi ZG, Muller JE. Efficacy of nifedipine therapy for refractory angina pectoris. Am Heart J 1982; 104: 672-81.
6. ACC/AHA/ACP-ACIM Guidelines for the management of patients with chronic stable angina. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC 2003; 41: 159-68.
7. Попов И.В. Cравнение возможности развития привыкания к изосорбида динитрату и нифедипину, назначаемых в лекарственных формах пролонгированного действия, у больных стабильной стенокардией напряжения. Автореф дисс канд мед наук. Москва 2004.
8. The Holland Interuniversity Nifedipine/metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: a randomised, double-blind, placebo-controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986; 56: 400-13.
9. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988; 9: 354- 64.
10. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium channel blocker or diuretic in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72.
11. Poole-Wilson P, Lubsen J, Kirwan B, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): a randomised controlled trial. Lancet 2004; 364: 849-57.
12. Terry R. Nifedipine therapy in angina pectoris: evaluation of safety and side effects. Am Heart J 1982; 104: 681-9.
13. Марцевич С.Ю., Семенова Ю.Э., Кутишенко Н.П. Новый препарат нифедипина пролонгированного действия – нифедипин-ГИТС. Результаты двойного слепого рандомизированного исследования у больных со стабильной стенокардией напряжения. Кардиология 2001; 4: 23-6.
14. Марцевич С.Ю., Кутишенко Н.П., Дмитриева Н.А.. Проблема выбора лекарственного препарата при лечении артериальной гипертонии. Кардиоваск тер профил 2004; 3(3) ч.I: 100-4.
Review
For citations:
Martsevich S.Yu. Nifedipine: 30 years of clinical experience. Cardiovascular Therapy and Prevention. 2005;4(2):4-8. (In Russ.)
Views:
512
Email this article 
